Express Scripts (ESRX) 86.12 $ESRX Forget Gilead (GILD),

New Post Public Reply Private Reply Replies (0) Message Board

Apr 23, 2015 at 1:08 AM

Express Scripts (ESRX) 86.12 $ESRX

Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:09AM CDT
It's time we overlooked Gilead for some biotech growth stocks.
BIIB: 423.57 (+1.46), JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), GERN: 4.20 (-0.04), ABBV: 64.52 (+0.91)

Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs
PR Newswire - Tue Apr 21, 7:30AM CDT
Workers' compensation pharmacy spending increased 1.9 percent in 2014, as a 5.4 percent decrease in utilization helped offset a 7 percent increase in the cost per prescription, according to new data released today by Express Scripts (NASDAQ: ESRX).
ESRX: 86.12 (+0.02)

UnitedHealth's Earnings Deliver, but Risks Lurk Beneath the Surface
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Apr 20, 9:08PM CDT
Investors hoping for strong first-quarter numbers from the nation's largest insurer got what they were looking for last Friday. UnitedHealth Group Inc . topped forecasts, with revenue and earnings per share up 13% ...
CI: 130.25 (-0.45), HCA: 77.53 (-0.15), ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), UNH: 117.81 (-1.47)

Double-Digit Spike in Drug Costs Prescribes Profits for PBMs
Bruce Japsen, The Motley Fool - Motley Fool - Mon Apr 20, 8:21AM CDT
The spike in employer spending on prescription drugs is now forecast to jump around 10% for the next three years, according to a new report that puts pressure on companies to dramatically alter pharmacy benefits. And while that's bad news for...
ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), GILD: 104.18 (-1.02), UNH: 117.81 (-1.47), CVS: 101.23 (-0.18), AON: 97.20 (+0.10), ABBV: 64.52 (+0.91)

What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 18, 9:02AM CDT
Source: Wikimedia Commons . Chip and Dan Heath give valuable advice on making decisions in their book "Decisive: How to Make Better Choices in Life and Work". In the book, the Heath brothers recommend taking four actions to make better decisions:...
ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91)

AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 5:14PM CDT
AbbVie's (ABBV) its experimental HCV treatment was granted priority review in Japan.
BIIB: 423.57 (+1.46), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), ABBV: 64.52 (+0.91)

Why CVS Health And McKesson May Be Good Stock Picks
at Investor's Business Daily - Thu Apr 16, 4:54PM CDT
As March data pointed to a strong month for prescription drugs sold in the U.S., two stocks in the supply chain were singled out Thursday as "top ideas." In a drug supply-chain report, Evercore ISI singled out CVS Health (CVS) and drug-distribution...
ESRX: 86.12 (+0.02), MCK: 231.27 (-0.02), CAH: 91.50 (+1.15), CVS: 101.23 (-0.18), AET: 107.95 (-0.41)

UnitedHealth Up After Topping Views, Raising Outlook
at Investor's Business Daily - Thu Apr 16, 8:24AM CDT
Shares of UnitedHealth Group (UNH) moved higher Thursday after the nation's biggest health insurer topped first-quarter earnings and revenue views and raised its 2015 forecast, boosted by another strong performance from its Optum Health Services...
CI: 130.25 (-0.45), ANTM: 152.84 (-0.04), HCA: 77.53 (-0.15), ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), UNH: 117.81 (-1.47), CVS: 101.23 (-0.18), AET: 107.95 (-0.41), HUM: 180.01 (-0.12)

The Best Stock to Invest in Hep C
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 7:03AM CDT
Source: Gilead Sciences. The market for hepatitis C treatment is among the most lucrative for drugmakers, but it's also one of the most dynamically changing markets. Only 10 years ago, patients were treated with side effect-laden cocktails of drugs...
JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), MRK: 57.69 (+0.03), RGLS: 17.40 (-0.22), ABBV: 64.52 (+0.91), BMY: 66.60 (-0.21)

Express Scripts Set to Possibly Rebound After Yesterday's Selloff of 1.14%
Comtex SmarTrend(R) - Wed Apr 15, 4:21PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $86.37 to a high of $88.57. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $87.79 on volume of 4.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 86.12 (+0.02)

SmarTrend Watching for Potential Rebound in Shares of Express Scripts After 1.14% Loss
Comtex SmarTrend(R) - Wed Apr 15, 4:20PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $86.37 to a high of $88.57. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $87.79 on volume of 4.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ESRX: 86.12 (+0.02)

3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 9:52AM CDT
The biotech sector is witnessing changing dynamics with the focus shifting from large caps to smaller companies with high growth potential.
JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), CYTX: 0.96 (-0.09), GERN: 4.20 (-0.04), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), HSP: 87.80 (+0.04), NVS: 103.45 (-0.62)

UnitedHealth Eyes Biggest Earnings Gain In Years
at Investor's Business Daily - Mon Apr 13, 7:02AM CDT
UnitedHealth Group (UNH) is expected to produce its best performance in years when it reports first-quarter results Thursday, while its stock price continues to trade near record highs following a major acquisition at the end of March. Analysts...
CI: 130.25 (-0.45), ANTM: 152.84 (-0.04), ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), UNH: 117.81 (-1.47), CVS: 101.23 (-0.18), AET: 107.95 (-0.41), HUM: 180.01 (-0.12)

The Long Strange Trip Of Walgreens And Express Scripts
Dana Blankenhorn - at Seeking Alpha - Sat Apr 11, 9:57AM CDT

ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), WBA: 87.02 (-0.07), UNH: 117.81 (-1.47), CVS: 101.23 (-0.18)

A New Drug Could Halt Weight Gain in Patients Taking These Antipsychotics
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 11, 9:14AM CDT
Source: Alkermes Plc Alkermes Plc is developing a new antipsychotic drug that could remove a major side effect that is associated with atypical antipsychotic medicines, including Eli Lilly and Co. 's Zyprexa. Atypical antipsychotics are...
ESRX: 86.12 (+0.02), LLY: 72.30 (+0.09), ALKS: 62.60 (-0.24)

Don't Play On Takeover Rumors - Cramer's Mad Money (4/9/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Apr 10, 6:47AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, April 9. Sometimes, the market gets the correlations wrong. As the dollar got stronger yesterday, everyone thought this would mean weaker oil, which made every...
ACT: 295.22 (+0.69), PRGO: 201.50 (+8.68), TERP: 42.15 (+0.47), SPG: 189.11 (+0.28), BRCM: 46.18 (+2.20), ALTR: 42.78 (-0.46), MYL: 72.40 (-1.67), STZ: 115.99 (-1.30), AGN: 240.22 (+2.88), ESRX: 86.12 (+0.02), WBA: 87.02 (-0.07), NVAX: 8.51 (+0.09), SUNE: 27.27 (+0.56), HZNP: 30.96 (+0.10), COST: 146.98 (-0.36), AAL: 51.40 (+0.04), TEVA: 63.01 (-1.15), MAC: 83.25 (+0.65), TWTR: 51.73 (+0.41)

Express Scripts Rises 4.87% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Apr 09, 3:51PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $84.82 to a high of $89.25. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $85.39 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 86.12 (+0.02)

Look for Shares of Express Scripts to Potentially Pullback after Yesterday's 4.87% Rise
Comtex SmarTrend(R) - Thu Apr 09, 3:51PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $84.82 to a high of $89.25. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $85.39 on volume of 8.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 86.12 (+0.02)

Express Scripts climbs as Walgreens states interest in deals
By TOM MURPHY - AP - Thu Apr 09, 2:29PM CDT
Shares of Express Scripts jumped Thursday amid investor speculation that the pharmacy benefits manager's off-and-on relationship with Walgreens may take a torrid turn.
CTRX: 59.46 (-0.11), ESRX: 86.12 (+0.02), UNH: 117.81 (-1.47), CVS: 101.23 (-0.18), CCT.TO: 72.75 (-0.32), RAD: 8.32 (+0.39)

Stocks Wobble At Starting Line; Express Scripts Up, Altera Dips
at Investor's Business Daily - Thu Apr 09, 9:41AM CDT
Stocks toggled in and out of mixed terrain in the early going Thursday. A half-hour after the open, the Dow Jones industrial average and the S&P 500 were down a fraction each. The Nasdaq was up by an equal amount. Volume started mixed, up 37% on the...
NOAH: 32.18 (+0.70), CTRX: 59.46 (-0.11), ESRX: 86.12 (+0.02), AKRX: 53.70 (-1.69), ALTR: 42.78 (-0.46), UNH: 117.81 (-1.47), INTC: 32.70 (+0.27), ATHM: 52.09 (+0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Plata Hits $1 Billion ARR in Record Digital Bank Growth

Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

National Showrooms Expands into Virginia with Key Buy

A New Chapter for Greenwich Kitchens I'll tell you what's catching my eye this time—National Kitchen & Bath Showrooms are making their move into Virginia by snapping up Greenwich Kitchens, a well-regarded name in the local kitchen and bath scene. Founded back in '78, Greenwich Kitchens has been a staple in the Virginia Beach and Hampton Roads areas for nearly half a...

Senté’s Heparan Sulfate Pairing: Peer-Reviewed Success

Senté's Science-Driven Approach in Skincare Alright, cutting through the skincare noise, Senté Labs has pulled off something impressive—not just another jar of promises but actual, peer-reviewed science backing their Defense C Serum. Published in the Journal of Cosmetic Dermatology, this study isn't just talk about ingredients; it's a show of real results. This isn't...

De¹ Unveils Tokenization Model on BNB Chain

De¹'s Bold Move into Enhanced Digital Finance Just when you thought the financial landscape couldn’t get any more complex, De¹ steps into the ring with its Tokenized Asset World on the BNB Chain—a move that's stirring the pot of tokenized finance in more ways than one. For old-school investors who thrive on waving outlandish stock bets, this crypto narrative is a...

Sarah Weede: A Force in Veterans Services Leadership

Saluting a Veteran's Advocate Amidst a world obsessed with bottom lines and market swings, it’s refreshing to spotlight someone like Sarah R. Weede. She's not about the Wall Street grind but you better believe her drive and dedication rival any big-shot CEO. Leadership in Veterans Services Sarah Weede's story starts with substantial roots planted in serving those who...

Tumor Ablation Market: Charting a Billion-Dollar Surge

Cancer's Unforgiving Climb: Opportunity Amidst Challenge Looking at the current state of the global tumor ablation market, one thing's clear—it's on a sort of upward swing you'd expect trains to make, riding the rails of rising cancer rates and technological advancements. At least that's what the folks at Wissen Research are banking on, projecting a leap to $1.8 billion...

BETR's Legal Clash: Investor Action Deadline Nears

BETR's Woes in the Legal Spotlight Investors who’ve been keeping an eye on Better Home & Finance Holding Company—trading as BETR on NASDAQ—might wanna pinch themselves. Not every day do you see a class action lawsuit waiting on the horizon like this one. The folks over at Schall, Brown & Schwartz LLP, those wily veterans in shareholder rights litigation, are...

Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...